“Diabetic Retinopathy Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Retinopathy Market.
The Diabetic Retinopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Diabetic Retinopathy Pipeline Report:
Companies across the globe are diligently working toward developing novel Diabetic Retinopathy treatment therapies with a considerable amount of success over the years.
Diabetic Retinopathy companies working in the treatment market are Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd., Kodiak Sciences Inc, and others, are developing therapies for the Diabetic Retinopathy treatment
Emerging Diabetic Retinopathy therapies in the different phases of clinical trials are- PL8177, ABI-110, OTX-TKI, MS-553, OTT166, RC28-E injection, KSI-301, and others are expected to have a significant impact on the Diabetic Retinopathy market in the coming years.
In June 2025, Perfuse Therapeutics, Inc., a biopharmaceutical company focused on developing breakthrough therapies for ischemia-related eye diseases, announced positive outcomes from two Phase 2 clinical trials of PER-001. This innovative treatment targets two major causes of blindness worldwide: glaucoma and diabetic retinopathy. Both six-month, randomized, controlled studies evaluated PER-001, a first-in-class endothelin antagonist delivered via a slow-release, dissolvable implant injected into the eye’s vitreous every six months. In both trials, PER-001 showed a significant improvement in vision compared to the control group.
In May 2025, The FDA has granted approval to Roche’s Susvimo (ranibizumab injection) at a 100 mg/mL dose for the treatment of diabetic retinopathy (DR). It is the first and only FDA-approved continuous delivery therapy proven to preserve vision in DR patients with a single refill required every nine months. This approval is supported by positive data from the Phase III Pavilion trial (NCT04503551).
In May 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR), a serious eye condition that impacts nearly 10 million people in the US and over 100 million worldwide. Susvimo is the first and only continuous delivery therapy approved by the FDA that has demonstrated the ability to preserve vision in DR patients with only one refill every nine months. The treatment is now available in the US for retina specialists and patients with DR who have previously shown a positive response to at least two anti-vascular endothelial growth factor (VEGF) injections.
In January 2025, The US-based biotechnology company Ocugen administered the first dose in a multicenter Phase I trial of OCU200 for treating diabetic macular edema (DMO).
In September 2024, MSD (Merck & Co) and its subsidiary EyeBio have initiated the Phase IIb/III BRUNELLO clinical trial for Restoret (MK-3000, previously EYE103) aimed at treating diabetic macular oedema (DME). This randomized, double-masked trial will evaluate the efficacy and safety of two different doses of intravitreal (IVT) Restoret compared to the active control, ranibizumab, in DME patients
Diabetic Retinopathy Overview
One eye-related consequence of diabetes is diabetic retinopathy. Damage to the blood vessels in the retina, the light-sensitive tissue in the back of the eye, is the root cause of it. Diabetic retinopathy may initially only produce minor vision impairment or no symptoms at all. But blindness may result from it. Any person with type 1 or type 2 diabetes has the potential to acquire the illness.
Get a Free Sample PDF Report to know more about Diabetic Retinopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight
Emerging Diabetic Retinopathy Drugs Under Different Phases of Clinical Development Include:
PL8177: Palatin Technologies
ABI-110: Avirmax Biopharma
OTX-TKI: Ocular Therapeutix, Inc.
MS-553: MingSight Pharmaceuticals, Inc
OTT166: OcuTerra Therapeutics, Inc.
RC28-E injection: RemeGen Co., Ltd.
KSI-301: Kodiak Sciences Inc
Diabetic Retinopathy Route of Administration
Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Diabetic Retinopathy Molecule Type
Diabetic Retinopathy Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Diabetic Retinopathy Pipeline Therapeutics Assessment
Diabetic Retinopathy Assessment by Product Type
Diabetic Retinopathy By Stage and Product Type
Diabetic Retinopathy Assessment by Route of Administration
Diabetic Retinopathy By Stage and Route of Administration
Diabetic Retinopathy Assessment by Molecule Type
Diabetic Retinopathy by Stage and Molecule Type
DelveInsight’s Diabetic Retinopathy Report covers around 55+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Diabetic Retinopathy product details are provided in the report. Download the Diabetic Retinopathy pipeline report to learn more about the emerging Diabetic Retinopathy therapies
Some of the key companies in the Diabetic Retinopathy Therapeutics Market include:
Key companies developing therapies for Diabetic Retinopathy are – Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, Palatin Technologies, Valo Health, EyePoint Pharmaceuticals, Kubota Vision, MingSight Pharmaceuticals, Oxurion, Aerie Pharmaceuticals, AsclepiX Therapeutics, Ocugen, Ashvattha Therapeutics, Stealth BioTherapeutics, and others.
Diabetic Retinopathy Pipeline Analysis:
The Diabetic Retinopathy pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
Diabetic Retinopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Diabetic Retinopathy drugs and therapies
Diabetic Retinopathy Pipeline Market Drivers
High healthcare Expenditure, increase in patient awareness about diabetes, presence of well-established healthcare infrastructure and favorable reimbursement framework are some of the important factors that are fueling the Diabetic Retinopathy Market.
Diabetic Retinopathy Pipeline Market Barriers
However, poor access to care, out-of-pocket expenses, insufficient patient knowledge or awareness of Diabetic Retinopathy and other factors are creating obstacles in the Diabetic Retinopathy Market growth.
Scope of Diabetic Retinopathy Pipeline Drug Insight
Coverage: Global
Key Diabetic Retinopathy Companies: Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd., Kodiak Sciences Inc, and others
Key Diabetic Retinopathy Therapies: PL8177, ABI-110, OTX-TKI, MS-553, OTT166, RC28-E injection, KSI-301, and others
Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers
Request for Sample PDF Report for Diabetic Retinopathy Pipeline Assessment and clinical trials
Table of Contents
1. Diabetic Retinopathy Report Introduction
2. Diabetic Retinopathy Executive Summary
3. Diabetic Retinopathy Overview
4. Diabetic Retinopathy- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Retinopathy Pipeline Therapeutics
6. Diabetic Retinopathy Late Stage Products (Phase II/III)
7. Diabetic Retinopathy Mid Stage Products (Phase II)
8. Diabetic Retinopathy Early Stage Products (Phase I)
9. Diabetic Retinopathy Preclinical Stage Products
10. Diabetic Retinopathy Therapeutics Assessment
11. Diabetic Retinopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Retinopathy Key Companies
14. Diabetic Retinopathy Key Products
15. Diabetic Retinopathy Unmet Needs
16 . Diabetic Retinopathy Market Drivers and Barriers
17. Diabetic Retinopathy Future Perspectives and Conclusion
18. Diabetic Retinopathy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Guarav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
